Literature DB >> 1309851

Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells.

S Singh1, S R Ross, M Acena, D A Rowley, H Schreiber.   

Abstract

Inoculated immunogenic cancer cells after initial growth are potentially rejected by specific host immunity; however, the outcome of the interaction between host and inoculated cancer cells is a function of multiple factors including the route of inoculation, the number of cells, the density of antigens on the injected cancer cells, and the state of the immune system of the host. In the present study, we have examined a different kind of variable: the stroma that inoculated tumor cells initially reside in. The impetus to examine this factor arises from observations that cancer cells from several lines inoculated as fragments of solid tumors often grow progressively, whereas the same number or more than 10-fold larger numbers of identical type cells injected as a suspension are rejected, even though fragments or suspended cells are both tumorigenic at the same doses in nude mice. In the present studies, we found that: (a) indeed, cancer cells inoculated as fragments were more tumorigenic than cancer cells in suspension; (b) the tumorigenicity of suspended cancer cells was increased by injection of the cells into polyurethane sponge implants; (c) cancer cells were more tumorigenic embedded in syngeneic stroma than in transgenic antigenic stroma expressing the K216 major histocompatibility complex class I antigen; and (d) antigenic, bone marrow-derived, stromal components (presumably passenger leukocytes) were sufficient to cause rejection of immunogenic but antigenically unrelated cancer.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1992        PMID: 1309851      PMCID: PMC2119086          DOI: 10.1084/jem.175.1.139

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  20 in total

1.  Major histocompatibility complex class I and unique antigen expression by murine tumors that escaped from CD8+ T-cell-dependent surveillance.

Authors:  P L Ward; H K Koeppen; T Hurteau; D A Rowley; H Schreiber
Journal:  Cancer Res       Date:  1990-07-01       Impact factor: 12.701

2.  Isolation of the MHC genes encoding the tumour-specific class I antigens expressed on a murine fibrosarcoma.

Authors:  H J Stauss; R Linsk; A Fischer; S Watts; D Banasiak; A Haberman; I Clark; J Forman; M McMillan; H Schreiber
Journal:  J Immunogenet       Date:  1986 Apr-Jun

3.  Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers.

Authors:  P Garin-Chesa; L J Old; W J Rettig
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

4.  Systemic alteration induced in mice by ultraviolet light irradiation and its relationship to ultraviolet carcinogenesis.

Authors:  M S Fisher; M L Kripke
Journal:  Proc Natl Acad Sci U S A       Date:  1977-04       Impact factor: 11.205

5.  In vitro migration of lymphocytes through collagen matrix: arrested locomotion in tumor-infiltrating lymphocytes.

Authors:  K G Applegate; C M Balch; N R Pellis
Journal:  Cancer Res       Date:  1990-11-15       Impact factor: 12.701

6.  The influence of MHC-compatible and MHC-incompatible antigen-presenting cells on the survival of MHC-compatible cultured murine keratinocyte allografts.

Authors:  P S Ramrakha; R J Sharp; H Yeoman; M A Stanley
Journal:  Transplantation       Date:  1989-10       Impact factor: 4.939

7.  Further characterization of immunological unresponsiveness induced in mice by ultraviolet radiation. Growth and induction of nonultraviolet-induced tumors in ultraviolet-irradiated mice.

Authors:  M L Kripke; R M Thorn; P H Lill; C I Civin; N H Pazmiño; M S Fisher
Journal:  Transplantation       Date:  1979-09       Impact factor: 4.939

8.  UV radiation-induced tumors in haired mice: identification as squamous cell carcinomas.

Authors:  W L Morison; M S Jerdan; T L Hoover; E R Farmer
Journal:  J Natl Cancer Inst       Date:  1986-11       Impact factor: 13.506

9.  Tumor antigens defined by cloned immunological probes are highly polymorphic and are not detected on autologous normal cells.

Authors:  P L Ward; H Koeppen; T Hurteau; H Schreiber
Journal:  J Exp Med       Date:  1989-07-01       Impact factor: 14.307

10.  Animals bearing malignant grafts reject normal grafts that express through gene transfer the same antigen.

Authors:  G A Perdrizet; S R Ross; H J Stauss; S Singh; H Koeppen; H Schreiber
Journal:  J Exp Med       Date:  1990-04-01       Impact factor: 14.307

View more
  50 in total

1.  Promotion of tumor invasion by cooperation of granulocytes and macrophages activated by anti-tumor antibodies.

Authors:  E Barbera-Guillem; K F May; J K Nyhus; M B Nelson
Journal:  Neoplasia       Date:  1999-11       Impact factor: 5.715

Review 2.  Targeting stroma to treat cancers.

Authors:  Boris Engels; Donald A Rowley; Hans Schreiber
Journal:  Semin Cancer Biol       Date:  2011-12-24       Impact factor: 15.707

3.  Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake.

Authors:  Markus Loeffler; Jörg A Krüger; Andreas G Niethammer; Ralph A Reisfeld
Journal:  J Clin Invest       Date:  2006-06-22       Impact factor: 14.808

Review 4.  "It is the antigen(s), stupid" and other lessons from over a decade of vaccitherapy of human cancer.

Authors:  Matthew R Buckwalter; Pramod K Srivastava
Journal:  Semin Immunol       Date:  2008-08-20       Impact factor: 11.130

Review 5.  Targeting the tumour stroma to improve cancer therapy.

Authors:  Kenneth C Valkenburg; Amber E de Groot; Kenneth J Pienta
Journal:  Nat Rev Clin Oncol       Date:  2018-06       Impact factor: 66.675

6.  Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancer.

Authors:  David C Binder; Boris Engels; Ainhoa Arina; Ping Yu; James M Slauch; Yang-Xin Fu; Theodore Karrison; Byron Burnette; Christian Idel; Ming Zhao; Robert M Hoffman; David H Munn; Donald A Rowley; Hans Schreiber
Journal:  Cancer Immunol Res       Date:  2013-08       Impact factor: 11.151

Review 7.  Immunotherapy I: Cyclosine gene transfer strategies.

Authors:  M P Colombo; G Forni
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

8.  Prognostic Significance of Stromal Versus Intratumoral Infiltrating Lymphocytes in Different Subtypes of Breast Cancer Treated With Cytotoxic Neoadjuvant Chemotherapy.

Authors:  Thaer Khoury; Vidya Nagrale; Mateusz Opyrchal; Xuan Peng; Dan Wang; Song Yao
Journal:  Appl Immunohistochem Mol Morphol       Date:  2018-09

9.  Transferable anticancer innate immunity in spontaneous regression/complete resistance mice.

Authors:  Amy M Hicks; Gregory Riedlinger; Mark C Willingham; Martha A Alexander-Miller; C Von Kap-Herr; Mark J Pettenati; Anne M Sanders; Holly M Weir; Wei Du; Joseph Kim; Andrew J G Simpson; Lloyd J Old; Zheng Cui
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-08       Impact factor: 11.205

Review 10.  Innate and adaptive immune cells in the tumor microenvironment.

Authors:  Thomas F Gajewski; Hans Schreiber; Yang-Xin Fu
Journal:  Nat Immunol       Date:  2013-10       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.